Literature DB >> 16487513

Dual treatment with COX-2 inhibitor and sodium arsenite leads to induction of surface Fas Ligand expression and Fas-Ligand-mediated apoptosis in human melanoma cells.

Vladimir N Ivanov1, Tom K Hei.   

Abstract

Most human melanomas express Fas receptor on the cell surface, and treatment with exogenous Fas Ligand (FasL) efficiently induces apoptosis of these cells. In contrast, endogenous surface expression of FasL is suppressed in Fas-positive melanomas. We report here the use of a combination of sodium arsenite, an inhibitor of NF-kappaB activation, and NS398, a cyclooxygenase-2 (COX-2) inhibitor, for restoration of the surface FasL expression. We observed a large increase of Fas-mediated apoptosis in Fas-positive melanomas. This was due to induction of FasL surface expression and increased susceptibility to Fas death signaling after arsenite and NS398 treatment. Furthermore, silencing COX-2 expression by specific RNAi also effectively increased surface FasL expression following arsenite treatment. Upregulation of the surface FasL levels was based on an increase in the efficiency of translocation to the cell surface and stabilization of FasL protein on the cell surface, rather than on acceleration of the FasL gene transcription. Data obtained demonstrate that the combination of arsenite with inhibitors of COX-2 may affect the target cancer cells via induction of FasL-mediated death signaling.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16487513      PMCID: PMC4376328          DOI: 10.1016/j.yexcr.2006.01.003

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  93 in total

Review 1.  IKK/NF-kappaB signaling: balancing life and death--a new approach to cancer therapy.

Authors:  Jun-Li Luo; Hideaki Kamata; Michael Karin
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Regulation of Fas-dependent activation-induced T cell apoptosis by cAMP signaling: a potential role for transcription factor NF-kappa B.

Authors:  V N Ivanov; R K Lee; E R Podack; T R Malek
Journal:  Oncogene       Date:  1997-05-22       Impact factor: 9.867

3.  Cellular localization and function of Fas ligand (CD95L) in tumors.

Authors:  Masayuki Kurooka; Gerard J Nuovo; Michael A Caligiuri; Gary J Nabel
Journal:  Cancer Res       Date:  2002-03-01       Impact factor: 12.701

Review 4.  The paradox of arsenic: molecular mechanisms of cell transformation and chemotherapeutic effects.

Authors:  Ann M Bode; Zigang Dong
Journal:  Crit Rev Oncol Hematol       Date:  2002-04       Impact factor: 6.312

Review 5.  Apoptosis in cancer--implications for therapy.

Authors:  Henning Schulze-Bergkamen; Peter H Krammer
Journal:  Semin Oncol       Date:  2004-02       Impact factor: 4.929

6.  Nude rat models for human tumor metastasis to CNS. Procedures for intracarotid delivery of cancer cells and drugs.

Authors:  A T Myklebust; A Helseth; K Breistøl; W A Hall; O Fodstad
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

7.  Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-kappa B activation through inhibition of activation of I kappa B alpha kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis.

Authors:  Shishir Shishodia; Dimpy Koul; Bharat B Aggarwal
Journal:  J Immunol       Date:  2004-08-01       Impact factor: 5.422

8.  H(2)O(2) induces upregulation of Fas and Fas ligand expression in NGF-differentiated PC12 cells: modulation by cAMP.

Authors:  F Facchinetti; S Furegato; S Terrazzino; A Leon
Journal:  J Neurosci Res       Date:  2002-07-15       Impact factor: 4.164

9.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential.

Authors:  M Tsujii; S Kawano; R N DuBois
Journal:  Proc Natl Acad Sci U S A       Date:  1997-04-01       Impact factor: 11.205

10.  Inhibition of melanoma growth and metastasis by ATF2-derived peptides.

Authors:  Anindita Bhoumik; Lisa Gangi; Ze'ev Ronai
Journal:  Cancer Res       Date:  2004-11-15       Impact factor: 12.701

View more
  7 in total

1.  Suppression of the proinflammatory response of metastatic melanoma cells increases TRAIL-induced apoptosis.

Authors:  Vladimir N Ivanov; Michael A Partridge; Sarah X L Huang; Tom K Hei
Journal:  J Cell Biochem       Date:  2011-02       Impact factor: 4.429

2.  Regulation of apoptosis in human melanoma and neuroblastoma cells by statins, sodium arsenite and TRAIL: a role of combined treatment versus monotherapy.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2011-12       Impact factor: 4.677

3.  A role for TRAIL/TRAIL-R2 in radiation-induced apoptosis and radiation-induced bystander response of human neural stem cells.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Apoptosis       Date:  2014-03       Impact factor: 4.677

4.  Sodium arsenite accelerates TRAIL-mediated apoptosis in melanoma cells through upregulation of TRAIL-R1/R2 surface levels and downregulation of cFLIP expression.

Authors:  Vladimir N Ivanov; Tom K Hei
Journal:  Exp Cell Res       Date:  2006-09-28       Impact factor: 3.905

5.  Sensitivity to sodium arsenite in human melanoma cells depends upon susceptibility to arsenite-induced mitotic arrest.

Authors:  Samuel C McNeely; Alex C Belshoff; B Frazier Taylor; Teresa W-M Fan; Michael J McCabe; Allan R Pinhas; J Christopher States
Journal:  Toxicol Appl Pharmacol       Date:  2008-02-05       Impact factor: 4.219

6.  Sequential treatment by ionizing radiation and sodium arsenite dramatically accelerates TRAIL-mediated apoptosis of human melanoma cells.

Authors:  Vladimir N Ivanov; Hongning Zhou; Tom K Hei
Journal:  Cancer Res       Date:  2007-06-01       Impact factor: 12.701

7.  Differential expression of interferon responsive genes in rodent models of transmissible spongiform encephalopathy disease.

Authors:  Michael J Stobart; Debra Parchaliuk; Sharon L R Simon; Jillian Lemaistre; Jozef Lazar; Richard Rubenstein; J David Knox
Journal:  Mol Neurodegener       Date:  2007-03-16       Impact factor: 14.195

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.